Pfizer to Remain Aggressive on Obesity Market After Setback

Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to...

Related Keywords

United States ,San Francisco ,California ,Michael Ermanediting ,Albert Bourla ,Novo Nordisk Wegovy ,Angela Hwang ,Novo Ozempic ,Eli Lilly ,Reuters ,Pfizer ,Chief Executive Albert Bourla ,Novo Nordisk ,New York Based ,Wall Street ,Chief Commercial Officer Angela Hwang ,Bill Berkrot ,Obesity ,Bese ,Weight Loss ,Weight Management ,Vaccine ,Vaccines ,Covid 19 Vaccine ,Coronavirus Vaccine ,Patient Safety ,A Scan Biometry ,A Scan Ultrasound Biometry ,Ea Scan ,Adverse Effects ,Side Effects ,New York ,Respiratory Syncytial Virus Infection ,Rsv Infection ,Espiratory Syncytial Virus Rsv Infection ,Scan ,Vision Care And Maintenance ,Cataracts ,Covid 19 ,019 Novel Coronavirus ,019 Ncov ,